Precision Biologics announces that a review, entitled "Generation of the therapeutic monoclonal antibody NEO-201, derived...
Precision Biologics awarded new US Patent on its lead monoclonal antibody NEO-201 for regulatory T-cell...
Precision Biologics presents new data from ongoing clinical trial combining NEO-201 with pembrolizumab at the...
7th INTERNATIONAL NEOANTIGEN SUMMIT, AMSTERDAM, NETHERLANDS, APRIL 29 - May 1, 2024 Accelerating Robust, Durable &...
IMMUNO 2024, LONDON, UK, APRIL 25 - 26, 2024 Day 1: Track 1: Discovery & Development:...
Precision Biologics will present recent scientific data at the American Association for Cancer Research (AACR)...
Dr. Philip M. Arlen, President & CEO of Precision Biologics, Inc. will deliver a scientific...
Natural killer (NK) cells are cellular components of the innate immune system that can recognize...
Precision Biologics presents new data from ongoing NEO-201 clinical trial at the Society for Immunotherapy...
Precision Biologics Announces the United States Patent and Trademark Office (USPTO) has granted a Patent...